Abstract
Quality of life (QoL) has become an important issue after early gastric cancer (EGC) treatment. We aimed to compare the QoL of EGC survivors after ESD (n = 241) or laparoscopic subtotal gastrectomy (n = 241) without recurrence and to evaluate the QoL over the 5-year period after adjusting for various confounding factors related to QoL. QoL related to the gastric cancer subscale (GCS) was significantly higher in the ESD group than surgery group (p < 0.001). After adjusting for all possible confounding factors, survivors who underwent ESD still had higher QoL related to CSG than those who underwent surgery. On the analysis of interaction effects for all QoL subscales, higher QoL related to GCS of ESD group than those of surgery group has been kept over time (p = 0.983). Therefore, we concluded that EGC survivors who undergo ESD have significantly better QoL related to GCS over a 5-year period after treatment than those who undergo surgery. This may be a useful consideration when selecting treatment modalities for patients with EGC.
Highlights
Quality of life (QoL) has become an important issue after early gastric cancer (EGC) treatment
Based on the accumulating data on comparable outcomes of endoscopic submucosal dissection (ESD) and surgery in terms of curability, 5-year survival rates, and adverse events, ESD is considered an optimal treatment for patients with EGC without risk of lymph node metastasis
The issue has been raised with improving QoL in long-term survivors after complete cure of EGCs
Summary
Quality of life (QoL) has become an important issue after early gastric cancer (EGC) treatment. Many western studies comparing ESD to surgery have reported comparable oncological safety and efficacy in cases of clear resection of EGCs, with low rates of procedure-related complications, high cure rates, and extremely infrequent metastatic recurrence, even in elderly patients with the poor general condition[6,7,8,9]. With these outstanding short and long-term outcomes of ESD, it is becoming an acceptable treatment for EGCs in patients with specific indications. We evaluated whether the QoL differences between the two groups would remain over time
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
